Semaglutide tablet 司美格鲁肽片

Enasidenib produced by Laos ASEAN Pharmaceutical (TLPH) has been approved for marketing by the Food and Drug Department (FDD) of the Lao Ministry of Health! Enasidenib produced by ASEAN Pharmaceutical, with the trade name Semaglutide, tablets, contains two specifications: 7mg*30 tablets/bottle and 14mg*30 tablets/bottle.
Enasidenib was approved for marketing by the US FDA in September 2019 for use in combination with diet and exercise to improve blood sugar control in patients with type 2 diabetes; in January 2023, it was approved by the FDA for the treatment of adult patients with type 2 diabetes who have not received diabetes medication before. Enasidenib tablets have been approved for marketing by the National Medical Products Administration (NMPA) for the treatment of type 2 diabetes.
As a star receptor agonist that has attracted much attention in the field of diabetes treatment in recent years, GLP-1RA plays a variety of precise and coordinated roles in the human body.
GLP-1RA activates the glucagon-like peptide-1 (GLP-1) receptor, stimulates insulin secretion in a glucose concentration-dependent manner, inhibits glucagon release, increases glucose uptake in muscle and adipose tissue, inhibits glucose synthesis in the liver, and exerts an excellent hypoglycemic effect through multiple targets. At the same time, GLP-1RA also plays a certain role in the gastrointestinal tract. It can not only delay the speed of gastric emptying and gastrointestinal motility, but also centrally suppress appetite and reduce food intake, thereby achieving the effect of lowering blood sugar.